Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.

Paul Andreas Compare Cloos; Stephan Christgau; Nina Lyubimova; Jean-Jacques Body; Per Qvist; Claus Christiansen

doi:10.1186/bcr607

Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.

Paul Andreas Compare Cloos, Stephan Christgau, Nina Lyubimova, Jean-Jacques Body, Per Qvist, Claus Christiansen

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

23 Citationer (Scopus)

Abstract

Udgivelsesdato: 2003

Originalsprog	Engelsk
Tidsskrift	Breast cancer research : BCR
Vol/bind	5
Udgave nummer	4
Sider (fra-til)	R103-9
DOI	https://doi.org/10.1186/bcr607
Status	Udgivet - 2003
Udgivet eksternt	Ja

Bibliografisk note

Keywords: Adult; Bone Neoplasms; Breast Neoplasms; Collagen; Collagen Type I; Female; Humans; Immunoassay; Middle Aged; Peptides

Adgang til dokumentet

10.1186/bcr607

Citationsformater

Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments. / Cloos, Paul Andreas Compare; Christgau, Stephan; Lyubimova, Nina; Body, Jean-Jacques; Qvist, Per; Christiansen, Claus.

I: Breast cancer research : BCR, Bind 5, Nr. 4, 2003, s. R103-9.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{a513599053f311dd8d9f000ea68e967b,

title = "Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.",

abstract = "BACKGROUND: Fragments of collagen type I containing the epitope AHDGGR (CTX) are generated during bone resorption. The aspartyl-glycine (DG) site within CTX is synthesised in the L-aspartyl peptide (alphaL) form, but converts to the age-modified forms L-isoaspartyl peptide (betaL) and D-aspartyl peptide (alphaD) over time. The purpose of the present study was to test the ability of the various CTX forms to identify breast cancer patients with bone metastases and to investigate whether such patients had an altered CTX excretion pattern. METHODS: In this cross-sectional study we compared CTX excretion in healthy premenopausal and postmenopausal women with CTX levels in patients with breast cancer. The breast cancer cohort comprised eight hypercalcemic patients with bone metastases (HC+), 100 normocalcemic patients with bone metastases (NC+) and 15 normocalcemic patients without bone metastases (NC-). RESULTS: In HC+ patients and NC+ patients, the excretion of alphaL CTX was highly increased compared with NC- patients (P < 0.01), with Z scores of 3.4 and 2.0, respectively. The excretion of the age-modified forms (betaL and alphaD CTX) was less increased in HC+ patients and in NC+ patients as compared with NC- patients, with Z scores of 2.2 and 1.0, respectively, for betaL CTX, and of 1.6 and 0.8, respectively, for alphaD CTX. CONCLUSION: Assays for the various isoforms of CTX have different sensitivities to identify patients affected by bone metastases. The alphaL CTX isoform reflecting resorption of young bone appeared to provide the best differentiation of patients affected by breast cancer-induced bone metastases. In conclusion, patients affected by metastatic bone disease present an altered excretion pattern of CTX isoforms.",

author = "Cloos, {Paul Andreas Compare} and Stephan Christgau and Nina Lyubimova and Jean-Jacques Body and Per Qvist and Claus Christiansen",

note = "Keywords: Adult; Bone Neoplasms; Breast Neoplasms; Collagen; Collagen Type I; Female; Humans; Immunoassay; Middle Aged; Peptides",

year = "2003",

doi = "10.1186/bcr607",

language = "English",

volume = "5",

pages = "R103--9",

journal = "Breast Cancer Research",

issn = "1465-5411",

publisher = "BioMed Central Ltd.",

number = "4",

}

TY - JOUR

T1 - Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.

AU - Cloos, Paul Andreas Compare

AU - Christgau, Stephan

AU - Lyubimova, Nina

AU - Body, Jean-Jacques

AU - Qvist, Per

AU - Christiansen, Claus

N1 - Keywords: Adult; Bone Neoplasms; Breast Neoplasms; Collagen; Collagen Type I; Female; Humans; Immunoassay; Middle Aged; Peptides

PY - 2003

Y1 - 2003

N2 - BACKGROUND: Fragments of collagen type I containing the epitope AHDGGR (CTX) are generated during bone resorption. The aspartyl-glycine (DG) site within CTX is synthesised in the L-aspartyl peptide (alphaL) form, but converts to the age-modified forms L-isoaspartyl peptide (betaL) and D-aspartyl peptide (alphaD) over time. The purpose of the present study was to test the ability of the various CTX forms to identify breast cancer patients with bone metastases and to investigate whether such patients had an altered CTX excretion pattern. METHODS: In this cross-sectional study we compared CTX excretion in healthy premenopausal and postmenopausal women with CTX levels in patients with breast cancer. The breast cancer cohort comprised eight hypercalcemic patients with bone metastases (HC+), 100 normocalcemic patients with bone metastases (NC+) and 15 normocalcemic patients without bone metastases (NC-). RESULTS: In HC+ patients and NC+ patients, the excretion of alphaL CTX was highly increased compared with NC- patients (P < 0.01), with Z scores of 3.4 and 2.0, respectively. The excretion of the age-modified forms (betaL and alphaD CTX) was less increased in HC+ patients and in NC+ patients as compared with NC- patients, with Z scores of 2.2 and 1.0, respectively, for betaL CTX, and of 1.6 and 0.8, respectively, for alphaD CTX. CONCLUSION: Assays for the various isoforms of CTX have different sensitivities to identify patients affected by bone metastases. The alphaL CTX isoform reflecting resorption of young bone appeared to provide the best differentiation of patients affected by breast cancer-induced bone metastases. In conclusion, patients affected by metastatic bone disease present an altered excretion pattern of CTX isoforms.

AB - BACKGROUND: Fragments of collagen type I containing the epitope AHDGGR (CTX) are generated during bone resorption. The aspartyl-glycine (DG) site within CTX is synthesised in the L-aspartyl peptide (alphaL) form, but converts to the age-modified forms L-isoaspartyl peptide (betaL) and D-aspartyl peptide (alphaD) over time. The purpose of the present study was to test the ability of the various CTX forms to identify breast cancer patients with bone metastases and to investigate whether such patients had an altered CTX excretion pattern. METHODS: In this cross-sectional study we compared CTX excretion in healthy premenopausal and postmenopausal women with CTX levels in patients with breast cancer. The breast cancer cohort comprised eight hypercalcemic patients with bone metastases (HC+), 100 normocalcemic patients with bone metastases (NC+) and 15 normocalcemic patients without bone metastases (NC-). RESULTS: In HC+ patients and NC+ patients, the excretion of alphaL CTX was highly increased compared with NC- patients (P < 0.01), with Z scores of 3.4 and 2.0, respectively. The excretion of the age-modified forms (betaL and alphaD CTX) was less increased in HC+ patients and in NC+ patients as compared with NC- patients, with Z scores of 2.2 and 1.0, respectively, for betaL CTX, and of 1.6 and 0.8, respectively, for alphaD CTX. CONCLUSION: Assays for the various isoforms of CTX have different sensitivities to identify patients affected by bone metastases. The alphaL CTX isoform reflecting resorption of young bone appeared to provide the best differentiation of patients affected by breast cancer-induced bone metastases. In conclusion, patients affected by metastatic bone disease present an altered excretion pattern of CTX isoforms.

U2 - 10.1186/bcr607

DO - 10.1186/bcr607

M3 - Journal article

C2 - 12818000

VL - 5

SP - R103-9

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 4

ER -